Both BBP and SBIO are ETFs. BBP has a lower 5-year return than SBIO (1.48% vs 2.15%). BBP has a higher expense ratio than SBIO (0.79% vs 0.5%). Below is the comparison between BBP and SBIO.
| BBP | SBIO | |
|---|---|---|
| Security Type | ETF | ETF |
| Segment | Equity: U.S. Biotech | Equity: U.S. Biotech |
| Family | Virtus | ALPS |
| Net Assets | $13.50M | $108.40M |
| Expense Ratio | 0.79% | 0.50% |
| Management Style | passive (index-based) | passive (index-based) |
| Dividend Yield | 0.00% | 0.00% |
| Underlying Index | LifeSci Biotechnology Products Index | Poliwogg Medical Breakthroughs Index |
| YTD Return | -20.92% | -37.51% |
| 1-Year Return | -25.26% | -43.65% |
| 3-Year Return | -0.99% | -7.86% |
| 5-Year Return | 1.48% | 2.15% |
| 10-Year Return | 0.00% | 0.00% |
BBP
BBP description
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. The Index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering or product candidate.
BBP performance & returns
| YTD Return | -20.92% |
| 1-Month Return | -3.39% |
| 3-Month Return | -8.42% |
| 1-Year Return | -25.26% |
| 3-Year Return | -0.99% |
| 5-Year Return | 1.48% |
| 10-Year Return | 0.00% |
BBP holdings
Top 10 Holdings (34.61% of Total Assets)
| Name | Symbol | % Assets |
|---|---|---|
| Sage Therapeutics Inc | SAGE | 4.86% |
| BeiGene Ltd ADR | BGNE | 4.34% |
| Amicus Therapeutics Inc | FOLD | 3.91% |
| Ultragenyx Pharmaceutical Inc | RARE | 3.54% |
| Blueprint Medicines Corp | BPMC | 3.51% |
| Retrophin Inc | RTRX | 3.17% |
| Halozyme Therapeutics Inc | HALO | 2.94% |
| Insmed Inc | INSM | 2.90% |
| United Therapeutics Corp | UTHR | 2.79% |
| Seagen Inc Ordinary Shares | SGEN | 2.65% |
BBP pros
None that we could think of.BBP cons
None that we could think of.Other relevant BBP comparisons
You may also want to check out the following BBP comparisons that investors often look for on Finny
SBIO
SBIO description
The Fund seeks investment results that correspond generally to the performance of index, the Poliwogg Medical Breakthroughs. The Index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration.
SBIO performance & returns
| YTD Return | -37.51% |
| 1-Month Return | -9.72% |
| 3-Month Return | -20.81% |
| 1-Year Return | -43.65% |
| 3-Year Return | -7.86% |
| 5-Year Return | 2.15% |
| 10-Year Return | 0.00% |
SBIO holdings
Top 10 Holdings (38.41% of Total Assets)
| Name | Symbol | % Assets |
|---|---|---|
| Mirati Therapeutics Inc | MRTX | 6.66% |
| Acceleron Pharma Inc | XLRN | 4.31% |
| United Therapeutics Corp | UTHR | 4.10% |
| Arrowhead Pharmaceuticals Inc | ARWR | 4.03% |
| Blueprint Medicines Corp | BPMC | 3.89% |
| Arena Pharmaceuticals Inc | ARNA | 3.40% |
| Emergent BioSolutions Inc | EBS | 3.28% |
| Allakos Inc | ALLK | 3.20% |
| Kodiak Sciences Inc | KOD | 2.79% |
| Vir Biotechnology Inc | VIR | 2.75% |
SBIO pros
None that we could think of.SBIO cons
The following are SBIO weaknesses from our perspective:
- SBIO net assets are $108.40 million. This fund is not a popular choice with retail investors.
- SBIO 3-year return is -6.63%, which is lower than the 3-year return of the benchmark index (MSCI ACWI NR USD), 9.04%.
- SBIO 5-year return is 2.15%, which is lower than the 5-year return of the benchmark index (MSCI ACWI NR USD), 8.14%.
Other relevant SBIO comparisons
You may also want to check out the following SBIO comparisons that investors often look for on Finny